Is docetaxel-carboplatin an alternative to paclitaxel-carboplatin in ovarian cancer?

被引：0
|
作者：
Vasey, PA
Coleman, R
Eggleton, SPH
Graham, J
Fleming, D
Paul, J
Reed, NS
Kaye, S
机构：
[1] CRC, Dept Med Oncol, Glasgow, Lanark, Scotland
[2] Weston Pk Hosp, Sheffield, S Yorkshire, England
[3] Bristol Oncol Ctr, Bristol, Avon, England
来源：
BRITISH JOURNAL OF CANCER | 1999年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [1] A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer
    Mori, Taisuke
    Hosokawa, Kenichi
    Kinoshita, Yoshiyuki
    Watanabe, Ai
    Yamaguchi, Takeshi
    Kuroboshi, Haruo
    Kato, Yoshiko
    Yasuda, Ansuke
    Fujita, Hiroyuki
    Nakata, Yoshinori
    Honjo, Hideo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (03) : 205 - 211
  • [2] A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer
    Taisuke Mori
    Kenichi Hosokawa
    Yoshiyuki Kinoshita
    Ai Watanabe
    Takeshi Yamaguchi
    Haruo Kuroboshi
    Yoshiko Kato
    Jinsuke Yasuda
    Hiroyuki Fujita
    Yoshinori Nakata
    Hideo Honjo
    International Journal of Clinical Oncology, 2007, 12 : 205 - 211
  • [3] Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
    Vasey, PA
    Jayson, GC
    Gordon, A
    Gabra, H
    Coleman, R
    Atkinson, R
    Parkin, D
    Paul, J
    Hay, A
    Kaye, SB
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (22): : 1682 - 1691
  • [4] Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
    Vasey, PA
    Atkinson, R
    Coleman, R
    Crawford, M
    Cruickshank, M
    Eggleton, P
    Fleming, D
    Graham, J
    Parkin, D
    Paul, J
    Reed, NS
    Kaye, SB
    BRITISH JOURNAL OF CANCER, 2001, 84 (02) : 170 - 178
  • [5] Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
    P A Vasey
    R Atkinson
    R Coleman
    M Crawford
    M Cruickshank
    P Eggleton
    D Fleming
    J Graham
    D Parkin
    J Paul
    N S Reed
    S B Kaye
    British Journal of Cancer, 2001, 84 : 170 - 178
  • [6] A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
    Isonishi, Seiji
    Suzuki, Masaaki
    Nagano, Hiroaki
    Takagi, Koichiro
    Shimauchi, Masahito
    Kawabata, Masakiyo
    Ochiai, Kazuhiko
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) : 154 - 159
  • [7] Consolidation docetaxel after paclitaxel-carboplatin chemotherapy in stage Ic-IV ovarian cancer.
    Matsumoto, R.
    Isonishi, S.
    Suzuki, M.
    Nagano, H.
    Takagi, K.
    Ochiai, K.
    Tanaka, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Paclitaxel-cisplatin vs. paclitaxel-Carboplatin in previously untreated ovarian cancer
    Neijt, JP
    Engelholm, SA
    Tuxen, M
    Sorensen, PG
    Hansen, M
    Sessa, C
    de Swart, CAM
    Hirsch, FR
    Witteveen, PO
    Lund, B
    Hansen, SW
    Palle, B
    Roer, O
    van Houwelingen, HC
    ANNALS OF ONCOLOGY, 1998, 9 : 65 - 65
  • [9] Five cases of skin desquamation due to bevacizumab combined with docetaxel-carboplatin in ovarian cancer
    Megumi Tokunaga
    Shuichi Nawata
    Takayuki Komoto
    Rei Mathuura
    Daisuke Ichikura
    Toru Watanabe
    Tadanori Sasaki
    International Cancer Conference Journal, 2023, 12 : 49 - 52
  • [10] Paclitaxel-carboplatin associated oligohydramnios
    Zagorodnikova, Ksenia A.
    Ulrikh, Elena A.
    Li, Olga A.
    Zazerskaya, Irina E.
    NEUROTOXICOLOGY AND TERATOLOGY, 2024, 104
12345